Biogen Inc. (BIIB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Biogen Inc. (BIIB) Healthcare & Pipeline Overview

Biogen Inc. is a prominent player in the biotechnology sector, specializing in therapies for neurological and neurodegenerative diseases, with a diverse portfolio including multiple sclerosis treatments and Alzheimer's disease therapies, positioning it strongly against competitors.

What Is the Investment Thesis for BIIB?

Biogen Inc. is positioned for growth driven by its strong portfolio of therapies for neurological diseases and a promising pipeline of investigational products. The company's current market capitalization stands at $31.8B, with a P/E ratio of 37.93, indicating a solid valuation relative to its earnings. Key growth catalysts include the potential success of its Alzheimer's treatments, which could capture significant market share in a high-demand area. Additionally, the company's ongoing collaborations with leading biotech firms may accelerate the development of new therapies, enhancing its competitive edge. However, investors should be aware of risks associated with patent expirations and increasing competition from biosimilars, which could impact revenue streams in the coming years.

Based on FMP financials and quantitative analysis

BIIB Key Highlights

Market Cap of $31.8B reflects strong market presence in biotechnology.

• P/E ratio of 37.93 indicates a competitive valuation in the healthcare sector.
• Profit margin of 13.9% demonstrates effective cost management and operational efficiency.
• Gross margin of 69.8% significantly exceeds industry averages, highlighting product pricing power.
• Beta of 0.16 suggests low volatility compared to the broader market, appealing to risk-averse investors.

Who Are BIIB's Competitors?

BIIB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BIIB's Key Strengths?

Diverse product portfolio addressing multiple neurological conditions.

• Strong financial performance with high gross margins.
• Established brand reputation in the biotechnology sector.
• Robust pipeline of investigational therapies for future growth.

What Are BIIB's Weaknesses?

Dependence on a limited number of key products for revenue.

• Exposure to patent expiration risks and biosimilar competition.
• Limited presence in emerging markets compared to competitors.
• Challenges in maintaining growth in a competitive landscape.

What Could Drive BIIB Stock Higher?

Potential FDA approval for new Alzheimer's therapies in 2026.

• Continued growth in sales of multiple sclerosis treatments.
• Development of new biosimilars to capture market share.
• Results from clinical trials for investigational therapies expected in 2026.
• Strategic partnerships enhancing research and development capabilities.

What Are the Key Risks for BIIB?

Rich valuation — a P/E of 37.93 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Increasing competition from biosimilars impacting revenue streams.
• Regulatory challenges and potential delays in product approvals.
• Dependence on a few key products for a significant portion of revenue.
• Market backlash against high drug prices affecting sales.

What Are the Growth Opportunities for BIIB?

• Growth opportunity 1: Biogen's Alzheimer's disease therapies, particularly ADUHELM and Lecanemab, represent a significant growth opportunity in a market projected to reach $20 billion by 2028. The increasing prevalence of Alzheimer's disease, combined with a growing acceptance of novel treatment modalities, positions Biogen to capture a substantial share of this lucrative market within the next five years.
• Growth opportunity 2: The expansion of Biogen's biosimilar portfolio, including products like BENEPALI and IMRALDI, is expected to drive revenue growth as healthcare systems seek cost-effective alternatives to expensive biologics.
• Growth opportunity 3: Biogen's ongoing research into neuroimmunology with investigational therapies such as BIIB135 and BIIB061 could unlock new treatment avenues for multiple sclerosis and other neurological disorders. The MS market alone is expected to grow to $25 billion by 2026, driven by the demand for innovative therapies that improve patient outcomes.
• Growth opportunity 4: The development of therapies targeting neuromuscular disorders, including BIIB067 and BIIB078, aligns with Biogen's strategic focus on high-need areas. The neuromuscular disease market is projected to grow significantly, offering Biogen the chance to establish a strong foothold in an underserved segment with substantial unmet medical needs.
• Growth opportunity 5: Biogen's commitment to advancing treatments for Parkinson's disease and related movement disorders through its pipeline products could lead to significant market opportunities. As awareness and diagnosis of Parkinson's increase, the market for these therapies is expected to grow, providing Biogen with avenues for expansion and innovation.

What Threats Does BIIB Face?

• Intense competition from both established and emerging biotech firms.
• Regulatory hurdles and potential delays in drug approvals.
• Market volatility affecting funding and investment in R&D.
• Potential backlash against high drug prices impacting sales.

What Are BIIB's Competitive Advantages?

• Strong portfolio of patented therapies providing a competitive edge.
• Robust R&D capabilities and a pipeline of innovative treatments.
• Established relationships with healthcare providers and research institutions.
• Expertise in navigating regulatory environments and securing approvals.

What Does BIIB Do?

Biogen Inc., founded in 1978, is headquartered in Cambridge, Massachusetts, and has become a pioneer in the biotechnology industry, focusing on therapies for neurological and neurodegenerative diseases. The company was established by a group of scientists who recognized the need for innovative treatments in a field that was largely underserved. Over the years, Biogen has evolved significantly, expanding its research and development capabilities and product offerings. Its portfolio includes well-known therapies such as TECFIDERA, AVONEX, and SPINRAZA, which address conditions like multiple sclerosis and spinal muscular atrophy. Additionally, Biogen has made strides in the Alzheimer's disease market with products like ADUHELM and Lecanemab. The company also develops various biosimilars and has a robust pipeline of investigational therapies targeting multiple neurological conditions. Biogen's strategic collaborations with other pharmaceutical companies enhance its research potential and market reach, allowing it to stay competitive in a rapidly evolving industry. With over 7,600 employees, Biogen is committed to advancing science and improving patient outcomes globally.

What Products and Services Does BIIB Offer?

• Discover and develop therapies for neurological and neurodegenerative diseases.
• Manufacture and deliver a range of medications for multiple sclerosis and spinal muscular atrophy.
• Provide biosimilars that offer cost-effective alternatives to branded biologics.
• Engage in collaborations and licensing agreements to enhance research capabilities.
• Conduct clinical trials to evaluate the safety and efficacy of new treatments.
• Focus on patient-centric solutions to improve health outcomes in chronic conditions.

How Does BIIB Make Money?

• Generate revenue through the sale of proprietary therapies and biosimilars.
• Leverage partnerships for research and development funding and market access.
• Utilize a robust pipeline of investigational drugs to drive future growth.
• Engage in strategic collaborations to enhance product offerings and market reach.

What Industry Does BIIB Operate In?

The drug manufacturing industry, particularly in the biotechnology sector, is experiencing rapid growth, driven by increasing demand for innovative therapies for chronic and complex diseases. The global market for neurological drugs is projected to expand significantly, with a focus on conditions such as Alzheimer's and multiple sclerosis, which are becoming more prevalent due to aging populations. Biogen Inc. operates in a competitive landscape with key players like Teva Pharmaceutical Industries Limited and United Therapeutics Corporation, where differentiation through innovative products and strong clinical data is essential for market success. The industry's growth rate is expected to remain robust as advancements in biotechnology continue to evolve.

Who Are BIIB's Key Customers?

• Healthcare providers and hospitals seeking innovative treatment options.
• Patients suffering from neurological and neurodegenerative diseases.
• Pharmaceutical distributors and wholesalers for product distribution.
• Insurance companies and payers involved in reimbursement decisions.

Company Profile

Biogen Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Christopher A. Viehbacher. BIIB has traded publicly since 1991.

Return on equity for Biogen Inc. stands at 7.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.7%, showing how much profit it generates from its asset base. BIIB trades at a trailing price-to-earnings ratio of 37.93, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 9.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.8%, the inverse of the P/E and a quick read on earnings relative to price.

BIIB Valuation & Market Position

With a $31.8B market cap, Biogen Inc. sits in the large-cap segment of the market. Analyst price targets span from $175.00 to $300.00, with a consensus of $245.88. At the current price of $215.43, that implies approximately 14% upside potential. Relative to its peer group, BIIB's quantitative score of 64/100 is roughly in line with the peer average of 74/100.

Quarterly Financial Performance: Biogen Inc.

Revenue for Biogen Inc. came in at $2.74B during Jun 2026, a 10.4% improvement versus the preceding quarter. The company recorded net income of $97.5M, with diluted EPS of $0.66. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, BIIB averaged $1.41 in diluted EPS.

Biogen Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.91 places it in the grey zone, a middle ground that warrants monitoring.

Biogen Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 17.3% above estimates on average.

Wall Street analysts project Biogen Inc. revenue of about $10.45B for fiscal 2026, with EPS near $12.49. The estimate reflects 23 contributing analysts.

Over the past six months, Biogen Inc. insiders filed 20 SEC Form 4 transactions — 7 sales and 13 purchases. On net that is roughly 20K shares acquired (about $335K) — insiders putting money in tends to read as conviction.

BIIB Financials

Next earnings report: Oct 29, 2026

BIIB Latest News

BIIB Analyst Consensus

BIIB MoonshotScore

Latest Biogen Inc. Analysis

BIIB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources